Overview
At a Glance
MOTS-c is a mitochondria-derived peptide encoded in the mitochondrial genome, often described as an "exercise mimetic" for its effects on cellular metabolism. Preclinical research shows it can improve insulin sensitivity, activate AMPK, and enhance physical performance in mice. It's gaining attention in longevity and biohacking communities, but there are no published human intervention trials. It remains a research peptide with significant gaps between the animal data and any clinical application.
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA — specifically by the 12S rRNA gene within the mitochondrial genome. It was discovered in 2015 by Changhan Lee and colleagues at the University of Southern California, making it one of the first identified mitochondria-derived peptides (MDPs) with hormone-like systemic effects (Lee et al., 2015).
The discovery of MOTS-c was significant because it demonstrated that mitochondria — traditionally viewed as cellular power plants — can encode signaling peptides that regulate metabolism throughout the body. MOTS-c is released from cells and travels through the bloodstream to act on distant tissues, functioning essentially as a mitochondria-derived hormone. This placed it at the intersection of mitochondrial biology, endocrinology, and metabolic medicine.
In preclinical studies, MOTS-c has demonstrated effects on insulin sensitivity, glucose homeostasis, fat metabolism, and exercise capacity. It activates AMPK (AMP-activated protein kinase), a master metabolic regulator often called the "metabolic switch," and has been described as an "exercise mimetic" — a compound that reproduces some of the metabolic benefits of physical exercise (Lee et al., 2015).
The first published human trial of MOTS-c (Lee et al., 2023) demonstrated improved insulin sensitivity in overweight, sedentary men — a milestone that moved the peptide from purely preclinical to early-stage clinical evidence. However, this was a small, early-phase study, and MOTS-c remains far from FDA approval (Lee et al., 2023).
Circulating MOTS-c levels naturally decline with age. This age-related decline, combined with the peptide's metabolic effects, has made it a subject of significant interest in the longevity and anti-aging research communities. MOTS-c levels also correlate with exercise — physically active individuals tend to have higher circulating levels, suggesting a connection between mitochondrial peptide signaling and the metabolic benefits of exercise.
Quick Facts
| Property | Details |
|---|---|
| Amino acid sequence | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg |
| Molecular weight | ~2,174 Da |
| Encoded by | Mitochondrial DNA (12S rRNA gene) |
| Key pathway | AMPK activation |
| Routes studied | Subcutaneous injection (human trial), intraperitoneal injection (mice) |
| Human trials | One published (Lee et al., 2023) — small, early-phase |
| FDA approval | None |
| Natural occurrence | Produced endogenously; declines with age |
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
Mitochondria-Derived Peptide Signaling
MOTS-c belongs to a recently discovered class of bioactive molecules called mitochondria-derived peptides (MDPs). These are small peptides encoded within the mitochondrial genome that can be secreted from cells and act on distant tissues — effectively allowing mitochondria to communicate with the rest of the body through the bloodstream (Lee et al., 2015).
This challenges the traditional view of mitochondria as purely intracellular organelles. MOTS-c demonstrates that mitochondrial DNA encodes not only the proteins of the electron transport chain but also signaling peptides with systemic hormonal functions.
AMPK Activation
The central mechanism of MOTS-c is activation of AMPK (AMP-activated protein kinase) — often called the "master metabolic switch." AMPK is activated when cellular energy is low (high AMP:ATP ratio) and triggers a cascade of metabolic responses designed to restore energy balance:
- Increased glucose uptake: AMPK promotes translocation of GLUT4 glucose transporters to the cell surface, enhancing insulin-independent glucose uptake into muscle and other tissues.
- Enhanced fatty acid oxidation: AMPK inhibits ACC (acetyl-CoA carboxylase), reducing malonyl-CoA levels and releasing the inhibition of CPT1 — the rate-limiting enzyme for mitochondrial fatty acid uptake and oxidation.
- Mitochondrial biogenesis: AMPK activates PGC-1α, a master regulator of mitochondrial biogenesis, leading to increased mitochondrial number and function.
- Inhibition of lipogenesis: AMPK suppresses de novo fat synthesis, redirecting metabolic flux away from fat storage.
- Autophagy promotion: AMPK activates cellular cleanup mechanisms (autophagy) that remove damaged proteins and organelles.
MOTS-c appears to activate AMPK by interfering with the folate-methionine cycle, which leads to intracellular accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) — a known endogenous AMPK activator (Lee et al., 2015).
Nuclear Translocation
A remarkable feature of MOTS-c is its ability to translocate to the cell nucleus under metabolic stress conditions. Once in the nucleus, MOTS-c interacts with transcription factors to regulate gene expression involved in antioxidant defense and metabolic adaptation. This nuclear translocation represents a direct communication pathway from mitochondria to the nuclear genome — a form of retrograde signaling (Kim et al., 2019).
Exercise Mimetic Properties
MOTS-c has been described as an "exercise mimetic" because its metabolic effects overlap substantially with those of physical exercise:
- Both activate AMPK
- Both increase glucose uptake and fatty acid oxidation
- Both promote mitochondrial biogenesis
- Both improve insulin sensitivity
- Circulating MOTS-c levels increase with exercise in humans
This does not mean MOTS-c replaces exercise — exercise produces a far broader range of physiological adaptations than any single pathway. However, the overlap is scientifically significant and suggests MOTS-c may be part of the molecular machinery through which exercise produces metabolic benefits (Kim et al., 2019).
Go Deeper
- Lee et al. (2015) — "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis" — Cell Metabolism
- Kim et al. (2019) — "MOTS-c nuclear translocation and adaptive stress response" — Cell Metabolism
- Reynolds et al. (2021) — "MOTS-c is an exercise-induced mitochondrial-encoded regulator" — Nature Communications
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Research
Discovery and Characterization
- Lee et al. (2015) — Cell Metabolism: The foundational paper identifying MOTS-c as a mitochondria-derived peptide encoded by the 12S rRNA gene. Demonstrated that MOTS-c activates AMPK, promotes glucose uptake, and regulates metabolic homeostasis. Treatment of mice with MOTS-c prevented age-dependent and diet-induced insulin resistance and obesity (Lee et al., 2015).
Preclinical Studies: Metabolic Effects
- Diet-induced obesity: MOTS-c administration prevented weight gain in mice fed a high-fat diet, reduced fat mass accumulation, and improved glucose tolerance — without affecting food intake (Lee et al., 2015).
- Age-related insulin resistance: Older mice treated with MOTS-c showed improved insulin sensitivity and glucose handling comparable to younger mice, suggesting the peptide can counteract age-related metabolic decline (Lee et al., 2015).
- Skeletal muscle metabolism: MOTS-c enhanced glucose uptake in skeletal muscle tissue through AMPK-dependent GLUT4 translocation, providing a mechanism for its insulin-sensitizing effects.
- Exercise interaction: Circulating MOTS-c levels increase with exercise in both mice and humans, suggesting it is part of the molecular response to physical activity. Exogenous MOTS-c administration improved exercise capacity in sedentary mice (Reynolds et al., 2021).
Nuclear Translocation and Stress Response
- Kim et al. (2019) — Cell Metabolism: Demonstrated that MOTS-c translocates to the cell nucleus under metabolic stress, where it regulates gene expression involved in antioxidant defense (particularly through the ARE/Nrf2 pathway). This nuclear function represents a novel form of mitochondria-to-nucleus communication and suggests MOTS-c plays a role in cellular stress adaptation (Kim et al., 2019).
Age-Related Decline
- Circulating levels decline with age: Multiple studies have documented that circulating MOTS-c levels decrease with aging in humans and mice. This decline correlates with age-related metabolic dysfunction, insulin resistance, and reduced exercise capacity (Lee et al., 2015).
- Genetic variants: A specific MOTS-c variant (m.1382A>C) found predominantly in Japanese and Northeast Asian populations is associated with exceptional longevity and reduced risk of type 2 diabetes, providing human genetic evidence supporting MOTS-c's role in metabolic health and aging (Fuku et al., 2015).
The First Human Trial: Lee et al. (2023)
The first published human trial of MOTS-c represents a significant milestone (Lee et al., 2023):
| Parameter | Details |
|---|---|
| Design | Randomized, double-blind, placebo-controlled |
| Population | Overweight, sedentary men |
| Intervention | MOTS-c administered via subcutaneous injection |
| Key finding | Improved insulin sensitivity (measured by hyperinsulinemic-euglycemic clamp — the gold standard) |
| Safety | No serious adverse events reported |
| Limitations | Small sample size; single study; short duration; men only |
This trial used the hyperinsulinemic-euglycemic clamp — considered the gold standard for measuring insulin sensitivity — which strengthens the quality of the finding. However, the study was small and represents early-phase clinical evidence. Larger, longer trials with diverse populations are needed to confirm and extend these findings.
Limitations of the Research
- One human trial. While promising, a single small study does not constitute robust clinical evidence. Replication by independent groups is needed.
- Primarily one research group. Much of the MOTS-c research originates from the Lee laboratory at USC. Independent replication is emerging but limited.
- Short-term data only. Long-term safety and efficacy in humans have not been evaluated.
- Limited population: The human trial included only overweight men. Effects in women, lean individuals, diabetic patients, and elderly populations are unknown.
- Mechanism details still emerging: While AMPK activation is established, the full receptor biology and signaling cascade of MOTS-c are not completely characterized.
Further Reading
- Lee et al. (2015) — Discovery of MOTS-c — Cell Metabolism
- Lee et al. (2023) — First human trial — Journal of Clinical Investigation
- Kim et al. (2019) — Nuclear translocation — Cell Metabolism
- Reynolds et al. (2021) — Exercise-induced MOTS-c — Nature Communications
- Fuku et al. (2015) — MOTS-c genetic variant and longevity
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA Status
MOTS-c has no FDA-approved indication. It is not classified as a drug, dietary supplement, or approved biologic. Any therapeutic use is experimental.
Clinical Applications Reported in Practice
| Application | Evidence Basis | Notes |
|---|---|---|
| Insulin sensitivity / metabolic health | Strong preclinical; one human trial | The most evidence-supported application. The human trial demonstrated improved insulin sensitivity using the gold-standard measurement method. Providers use MOTS-c for patients with insulin resistance, prediabetes, or metabolic syndrome. |
| Exercise enhancement / recovery | Preclinical | Based on exercise mimetic properties and the observation that MOTS-c levels correlate with physical activity. Some providers use it as an adjunct to exercise programs. |
| Anti-aging / longevity | Preclinical; genetic association data | Based on age-related decline in MOTS-c levels and the genetic association between a MOTS-c variant and exceptional longevity. No human longevity-specific trial exists. |
| Weight management | Preclinical | Mice treated with MOTS-c showed reduced weight gain on high-fat diets. Human weight loss data is not available. |
| Mitochondrial support | Mechanistically supported | MOTS-c promotes mitochondrial biogenesis through AMPK-PGC-1α signaling. Used by some providers for patients with mitochondrial dysfunction or fatigue. |
What MOTS-c Is NOT Used For
- Diabetes treatment: While it improves insulin sensitivity, MOTS-c is not a diabetes medication and should not replace established antidiabetic therapies.
- Exercise replacement: The "exercise mimetic" label can be misleading. MOTS-c reproduces some metabolic effects of exercise but not the full range of cardiovascular, musculoskeletal, and neurological benefits.
- Performance enhancement in athletes: While not specifically listed by WADA at time of writing, its non-approved status places it under the S0 category for tested athletes.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
MOTS-c is not FDA-approved. No official dosing guidelines exist. The information below reflects protocols used in the published human trial and commonly reported in clinical practice — it is provided for informational purposes only. Do not self-administer any peptide without guidance from a qualified healthcare provider. Dosing, preparation, and administration should be overseen by a licensed clinician.
Commonly Reported Protocols
| Route | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous injection | 5–10 mg | 3–5x per week | Subcutaneous administration is the route used in the published human trial. Abdominal injection is commonly reported. |
| Subcutaneous injection (loading) | 10 mg | Daily for 1–2 weeks | Some providers use a higher-frequency loading phase followed by a maintenance schedule. No published evidence supports this approach specifically. |
Sources: Lee et al. (2023) — dosing in human trial, Journal of Clinical Investigation; Lee et al. (2015) — preclinical dosing ranges.
Dose Considerations
MOTS-c dosing in the peptide therapy space is higher per injection than many other peptides (milligrams rather than micrograms), reflecting its molecular characteristics and the doses used in the human trial. Key considerations:
- The human trial established proof-of-concept at a specific dose; dose-response optimization has not been published
- Lower doses may be effective; higher doses have not been shown to produce greater benefit
- Endogenous MOTS-c circulates at much lower levels than therapeutic doses, suggesting supraphysiological dosing — the clinical implications of this are not fully characterized
Cycling
- Common protocol: 8–12 weeks on, 4 weeks off
- Maintenance: Some providers recommend ongoing use at reduced frequency (2–3x per week)
- No established optimal duration — cycling recommendations are convention-based
Administration Guidance
MOTS-c for subcutaneous use is supplied as a lyophilized powder requiring reconstitution. Preparation and administration should be demonstrated and supervised by your prescribing healthcare provider or pharmacist.
Storage
- Lyophilized powder: Store refrigerated (2–8°C / 36–46°F) or frozen for long-term storage
- Reconstituted solution: Refrigerate and use within 2–4 weeks
- Peptides are sensitive to temperature: Avoid repeated freeze-thaw cycles
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What Users Report
The published human trial (Lee et al., 2023) demonstrated improved insulin sensitivity — the only clinically validated endpoint. Other reported effects (energy, exercise performance, body composition) come from user reports and clinician observations, not controlled trials.
Reported Timeline
| Timepoint | What Users Typically Report |
|---|---|
| Week 1–2 | Users frequently report increased energy and improved exercise tolerance within the first 1–2 weeks. Some describe feeling "more energetic during workouts" and less fatigued during daily activities. These early effects are consistent with AMPK activation and enhanced mitochondrial function, though placebo effect cannot be excluded. |
| Week 2–4 | More consistent reports of improved exercise capacity, better recovery between workouts, and subtle body composition changes. Some users report improved fasting glucose readings if monitoring at home. |
| Week 4–8 | Users who combine MOTS-c with regular exercise report enhanced training adaptations — increased endurance, better stamina, and improved body composition. Some report measurable changes in metabolic markers (fasting glucose, HbA1c) at provider follow-ups. |
| Week 8+ | Reports of continued metabolic improvement. Long-term users describe sustained energy levels and metabolic health maintenance. Reports plateau rather than showing progressive improvement. |
Clinical Trial Results vs. User Reports
The published human trial provides important context:
- Validated: Improved insulin sensitivity was demonstrated using the gold-standard hyperinsulinemic-euglycemic clamp technique. This is a real, measurable metabolic improvement.
- Not validated in humans: Weight loss, exercise capacity enhancement, anti-aging effects, and subjective energy improvements have not been confirmed in controlled human studies.
- Consistent direction: User reports of improved energy and metabolic function are directionally consistent with the mechanisms demonstrated in preclinical research and the human trial, even though they have not been formally studied.
Interpretation Cautions
- MOTS-c users are typically also exercising. Many users adopt MOTS-c as part of an overall metabolic optimization program that includes exercise, dietary changes, and other interventions. Separating the peptide's contribution from lifestyle changes is not possible without controlled trials.
- Placebo effect. Subjective energy and exercise performance are highly susceptible to placebo effects.
- Selection bias. Users who share their experiences are disproportionately those who perceived positive results.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Reported Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site reaction | Uncommon | Mild redness, swelling, or tenderness at the injection site. Self-limiting. |
| Flushing / warmth | Uncommon | Transient sensation of warmth or mild facial flushing shortly after injection. Typically resolves within minutes to hours. |
| GI discomfort | Rare | Mild nausea or stomach upset reported infrequently. |
| Headache | Rare | Mild and transient. |
| Fatigue (paradoxical) | Rare | Some users report temporary tiredness in the first few days, possibly related to metabolic adjustment. |
Human Trial Safety Data
The Lee et al. (2023) trial reported no serious adverse events attributed to MOTS-c. Vital signs, standard blood chemistry, and hematological parameters remained within normal ranges throughout the study period (Lee et al., 2023). While encouraging, this was a small, short-duration study — long-term and larger-scale safety data is needed.
Theoretical Risks
- AMPK activation concerns: Chronic AMPK activation could theoretically affect cardiac function (AMPK plays complex roles in cardiac metabolism), suppress mTOR signaling (potentially affecting muscle growth), or interact with cancer biology (AMPK has both tumor-suppressive and tumor-promoting roles depending on context).
- Supraphysiological dosing: Therapeutic MOTS-c doses far exceed naturally circulating levels. The consequences of sustained supraphysiological MOTS-c exposure are unknown.
- Mitochondrial biology complexity: As a mitochondria-derived peptide, MOTS-c may have effects on mitochondrial dynamics, fusion/fission balance, and mitophagy that have not been fully characterized.
- Long-term effects unknown: No data beyond short-term treatment exists in humans.
- Drug interactions: No formal drug interaction studies have been conducted. Theoretical interactions with metformin (which also activates AMPK) and other metabolic medications should be considered.
Contraindications (Theoretical)
- Pregnancy and breastfeeding — no safety data
- Active cancer — due to complex AMPK-cancer interactions
- Type 1 diabetes — glucose-lowering effects could increase hypoglycemia risk
- Children and adolescents — no data
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
FDA Classification
| Action | Status | Impact |
|---|---|---|
| Therapeutic approval | None | MOTS-c has not been approved as a drug by the FDA. |
| Category 2 (2024) | Previously classified | FDA classified MOTS-c as not suitable for compounding, restricting pharmacy access. |
| Category 1 return | In progress | MOTS-c is returning to Category 1, which would restore compounding pharmacy access under standard 503A/503B compounding regulations. |
Endogenous vs. Exogenous Distinction
MOTS-c is produced naturally by the body — it is encoded in mitochondrial DNA and circulates in the bloodstream as an endogenous signaling peptide. This distinguishes it from purely synthetic peptides (like BPC-157) that do not exist as standalone molecules in the body. However, the endogenous nature of MOTS-c does not exempt it from FDA regulation when administered exogenously at therapeutic doses:
- Insulin is endogenous but heavily regulated as a pharmaceutical product
- Growth hormone is endogenous but requires a prescription
- The same regulatory framework applies to exogenous MOTS-c administration
Research Chemical Market
MOTS-c is available through research chemical suppliers and some compounding-adjacent vendors. Products vary in quality, purity, and accurate peptide content. Third-party testing is not mandated, and regulatory oversight is limited.
WADA Status
MOTS-c is not specifically named on the WADA prohibited list but falls under the S0 category (non-approved substances) for athletes subject to anti-doping testing. As a peptide that mimics exercise-induced metabolic effects, it could also be considered under growth factor or peptide hormone categories.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Typical Pricing
| Source | Typical Price Range | What You Get | Quality Assurance |
|---|---|---|---|
| Compounding pharmacy | $250–$400/month | Patient-specific preparation prescribed by a licensed provider. Lyophilized vial. | Highest — regulated pharmacy, USP standards, prescription required. |
| Research chemical supplier | $150–$300/month | Lyophilized powder vials labeled "for research only." | Variable — some provide COAs; quality varies between suppliers. |
Why MOTS-c Is More Expensive
MOTS-c is typically more expensive per month than many other peptides because:
- Higher dose per injection: MOTS-c is dosed in milligrams (5–10 mg), whereas many peptides are dosed in micrograms (250–500 mcg). This requires roughly 10–40x more raw peptide per injection.
- Multiple injections per week: At 3–5x weekly, monthly consumption is significant.
- Synthesis complexity: As a 16-amino-acid peptide with specific sequence requirements, synthesis is more involved than simpler small molecules.
Insurance Coverage
MOTS-c is not covered by any insurance plan. All costs are out-of-pocket.
Cost Comparison
| Treatment | Monthly Cost | Evidence Level |
|---|---|---|
| MOTS-c | $150–$400 | One human trial (insulin sensitivity); strong preclinical |
| Metformin | $4–$20 | Decades of Phase 3/4 data; FDA-approved for diabetes |
| Berberine | $15–$30 | Multiple human trials for metabolic effects |
| Semaglutide (Wegovy) | $300–$1,300 | Phase 3: ~15% weight loss; FDA-approved |
| Regular exercise | $0–$100 | Strongest evidence base for metabolic health |
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Myth: MOTS-c replaces exercise.
Answer: MOTS-c has been called an "exercise mimetic" because it activates some of the same metabolic pathways as exercise — particularly AMPK activation, glucose uptake, and fatty acid oxidation (Lee et al., 2015). However, exercise produces a vast range of benefits beyond AMPK activation: cardiovascular conditioning, musculoskeletal strengthening, neuroplasticity, mood regulation, bone density maintenance, and social engagement. No single compound can replicate this. MOTS-c may complement exercise, but it does not replace it.
Myth: MOTS-c is proven to extend lifespan.
Answer: A genetic variant of MOTS-c (m.1382A>C) has been associated with exceptional longevity in Japanese populations (Fuku et al., 2015), and circulating MOTS-c levels decline with age. These are interesting correlational findings, but they do not prove that exogenous MOTS-c administration extends lifespan. No longevity trial — in any species — has been published for exogenous MOTS-c.
Myth: MOTS-c is fully proven in humans.
Answer: One small human trial has been published showing improved insulin sensitivity (Lee et al., 2023). This is a meaningful milestone but represents early-stage clinical evidence. Full clinical validation requires larger trials, longer duration, diverse populations, dose-ranging studies, and independent replication. The research trajectory is promising but far from complete.
Myth: Since MOTS-c is natural, it must be safe.
Answer: MOTS-c is produced endogenously, which is sometimes cited as evidence of safety. However, administering a compound exogenously at supraphysiological doses is fundamentally different from natural production. Many endogenous compounds are harmful at high doses — cortisol, insulin, and thyroid hormone can all cause serious problems when administered in excess. Exogenous MOTS-c safety at therapeutic doses over extended periods has not been established.
Myth: MOTS-c works the same as metformin.
Answer: Both MOTS-c and metformin activate AMPK, and both improve insulin sensitivity. However, they work through different upstream mechanisms — metformin inhibits mitochondrial complex I, while MOTS-c interferes with the folate-methionine cycle. Their tissue-specific effects, side effect profiles, and optimal patient populations may differ substantially. Metformin has decades of clinical data across millions of patients; MOTS-c has one small human trial.
Myth: All MOTS-c products are the same.
Answer: Product quality varies by source. Compounding pharmacy preparations (when available) are made under regulated conditions. Research chemical products may contain variable amounts of actual peptide, degradation products, or impurities. Independent testing of peptide products has found significant quality variation across suppliers.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- MOTS-c is a mitochondria-derived peptide — a 16-amino-acid signaling molecule encoded by mitochondrial DNA that acts as a systemic metabolic regulator. Its discovery in 2015 opened a new field of mitochondrial endocrinology.
- It activates AMPK and promotes glucose uptake, fatty acid oxidation, mitochondrial biogenesis, and insulin sensitivity — effects that overlap substantially with exercise.
- The first human trial (Lee et al., 2023) demonstrated improved insulin sensitivity in overweight, sedentary men using the gold-standard measurement method. This is meaningful early-stage clinical evidence published in a respected journal (Lee et al., 2023).
- The research trajectory is promising but early. One small human trial does not constitute robust clinical validation. Larger, longer, and more diverse trials are needed.
- Circulating MOTS-c declines with age and correlates with exercise levels, placing it at the intersection of aging, metabolism, and physical activity research.
- It is not a replacement for exercise, metformin, or established metabolic therapies. It may be a complement to these approaches for appropriate patients.
- It is returning to Category 1 after FDA Category 2 classification in 2024, which would restore compounding pharmacy access.
- Cost is $150–$400/month and is not covered by insurance.
- The published research is in high-quality journals (Cell Metabolism, Nature Communications), which distinguishes MOTS-c from many compounds in the peptide space that rely on lower-tier publications.
Questions to Ask a Provider
- Based on my metabolic profile, does the available evidence support trying MOTS-c?
- Have you reviewed the Lee et al. (2023) human trial data?
- How does MOTS-c compare to metformin or other established options for my specific situation?
- Am I already exercising regularly? (MOTS-c may complement but should not replace physical activity)
- Where will the MOTS-c be sourced, and what quality testing has been performed?
- What monitoring (fasting glucose, HbA1c, insulin levels) is appropriate during treatment?
- What is the planned treatment duration and reassessment timeline?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Discovery & Mechanism
- Lee et al. (2015) — "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance" — Cell Metabolism
- Kim et al. (2019) — "Mitochondrial-derived peptide MOTS-c translocates to the nucleus to regulate adaptive stress response" — Cell Metabolism
Human Clinical Trial
Exercise & Aging
- Reynolds et al. (2021) — "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline" — Nature Communications
- Fuku et al. (2015) — "The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?" — Aging Cell
Regulatory & Classification
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
